Powell, Allison B.
Yadavilli, Sridevi
Saunders, Devin
Van Pelt, Stacey
Chorvinsky, Elizabeth
Burga, Rachel A.
Albihani, Shuroug
Hanley, Patrick J.
Xu, Zhenhua
Pei, Yanxin
Yvon, Eric S.
Hwang, Eugene I.
Bollard, Catherine M.
Nazarian, Javad
Cruz, Conrad Russell Y.
Funding for this research was provided by:
Alex's Lemonade Stand Foundation for Childhood Cancer (A Award)
Article History
Received: 12 April 2019
Accepted: 31 August 2019
First Online: 23 September 2019
Ethics approval and consent to participate
: Umbilical cord blood (UCB) samples were obtained from Dr. E.J. Shpall at the UT MD Anderson Cancer Center cord blood bank, using an IRB approved protocol (Pro00003896). Patient samples were obtained at Children’s National Medical Center from patients diagnosed with a malignant brain tumor (EH, IRB Pro00004033) after informed consent.
: Not applicable.
: CRYC, PH, and CB are co-founders and equity holders of Mana Therapeutics, a biotechnology company focusing on cell-based immune therapies. CRYC, CRYC, EY, RAB, and CB have intellectual property applications on technology similar to what is described in this manuscript, though not what was used here.